Paragraph 3
Where the product is a new medicinal product containing known constituents not hitherto used in combination for therapeutic purposes, the applicant shall, notwithstanding paragraph 1 above, provide particulars of the results of appropriate pharmacological and toxicological tests and of clinical trials in relation to that combination but it shall not be necessary to provide references relating to each individual constituent.